Print Page   |   Contact Us   |   Report Abuse   |   Sign In   |   Register
Community Search
News & Press: Industry News

Amgen loss 'a temporary blip' for Seattle biotech: Man behind Arch Venture's $400M fund speaks out

Wednesday, August 27, 2014   (0 Comments)
Posted by: Megan Jeffrey
Share |
Amgen loss 'a temporary blip' for Seattle biotech: Man behind Arch Venture's $400M fund speaks out | Puget Sound Business Journal 

more WBBA Calendar

10/9/2014
ETI-Problem Solving for Effective CAPA

Featured Partners
MPI ResearchAs a leading global provider, MPI Research delivers complete efficacy and safety testing

Membership Management Software Powered by YourMembership.com®  ::  Legal/Privacy